Uncovering the RNA-binding protein landscape in the pluripotency network of human embryonic stem cells.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
01 06 2021
Historique:
received: 03 06 2020
revised: 11 03 2021
accepted: 11 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 12 2 2022
Statut: ppublish

Résumé

Embryonic stem cell (ESC) self-renewal and cell fate decisions are driven by a broad array of molecular signals. While transcriptional regulators have been extensively studied in human ESCs (hESCs), the extent to which RNA-binding proteins (RBPs) contribute to human pluripotency remains unclear. Here, we carry out a proteome-wide screen and identify 810 proteins that bind RNA in hESCs. We reveal that RBPs are preferentially expressed in hESCs and dynamically regulated during early stem cell differentiation. Notably, many RBPs are affected by knockdown of OCT4, a master regulator of pluripotency, several dozen of which are directly targeted by this factor. Using cross-linking and immunoprecipitation (CLIP-seq), we find that the pluripotency-associated STAT3 and OCT4 transcription factors interact with RNA in hESCs and confirm the binding of STAT3 to the conserved NORAD long-noncoding RNA. Our findings indicate that RBPs have a more widespread role in human pluripotency than previously appreciated.

Identifiants

pubmed: 34077720
pii: S2211-1247(21)00544-1
doi: 10.1016/j.celrep.2021.109198
pii:
doi:

Substances chimiques

Proteome 0
RNA, Messenger 0
RNA-Binding Proteins 0
STAT3 Transcription Factor 0
STAT3 protein, human 0
DNA 9007-49-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109198

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Shlomi Dvir (S)

Faculty of Biology, Technion - Israel Institute of Technology, Haifa 320003, Israel.

Amir Argoetti (A)

Faculty of Biology, Technion - Israel Institute of Technology, Haifa 320003, Israel.

Chen Lesnik (C)

Faculty of Biology, Technion - Israel Institute of Technology, Haifa 320003, Israel.

Mark Roytblat (M)

Accellta LTD, Haifa 320003, Israel.

Kohava Shriki (K)

Accellta LTD, Haifa 320003, Israel.

Michal Amit (M)

Accellta LTD, Haifa 320003, Israel; Ephraim Katzir Department of Biotechnology Engineering, ORT Braude College, Karmiel 2161002, Israel.

Tamar Hashimshony (T)

Faculty of Biology, Technion - Israel Institute of Technology, Haifa 320003, Israel.

Yael Mandel-Gutfreund (Y)

Faculty of Biology, Technion - Israel Institute of Technology, Haifa 320003, Israel; Computer Science Department, Technion - Israel Institute of Technology, Haifa 320003, Israel. Electronic address: yaelmg@technion.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH